Twenty years of research on HPV vaccines based on genetically modified lactic acid bacteria: an overview on the gut-vagina axis

[1]  G. Scalia,et al.  Multiple HPV 16 infection with two strains: a possible marker of neoplastic progression , 2020, BMC Cancer.

[2]  H. Keyvani,et al.  The First Clinical Use of a Recombinant Lactococcus lactis Expressing Human Papillomavirus Type 16 E7 Oncogene Oral Vaccine: A Phase I Safety and Immunogenicity Trial in Healthy Women Volunteers , 2019, Molecular Cancer Therapeutics.

[3]  M. Sung,et al.  Oral administration of poly-gamma-glutamic acid significantly enhances the antitumor effect of HPV16 E7-expressing Lactobacillus casei in a TC-1 mouse model. , 2019, Journal of microbiology and biotechnology.

[4]  Kiyoko Kato,et al.  Safety and efficacy of mucosal immunotherapy using human papillomavirus (HPV) type 16 E7-expressing Lactobacillus-based vaccine for the treatment of high-grade squamous intraepithelial lesion (HSIL): the study protocol of a randomized placebo-controlled clinical trial (MILACLE study). , 2019, Japanese journal of clinical oncology.

[5]  H. Keyvani,et al.  Phase 1 Safety and Immunogenicity Trial of Recombinant Lactococcus lactis Expressing Human Papillomavirus Type 16 E6 Oncoprotein Vaccine , 2019, Molecular therapy. Methods & clinical development.

[6]  N. Inoue,et al.  Current issues regarding the application of recombinant lactic acid bacteria to mucosal vaccine carriers , 2019, Applied Microbiology and Biotechnology.

[7]  Tae Jin Kim,et al.  A phase 1/2a, dose-escalation, safety and preliminary efficacy study of oral therapeutic vaccine in subjects with cervical intraepithelial neoplasia 3 , 2019, Journal of gynecologic oncology.

[8]  H. Keyvani,et al.  Extracellular overproduction of E7 oncoprotein of Iranian human papillomavirus type 16 by genetically engineered Lactococcus lactis , 2019, BMC Biotechnology.

[9]  V. Ladero,et al.  Lactic Acid Bacteria as a Live Delivery System for the in situ Production of Nanobodies in the Human Gastrointestinal Tract , 2019, Front. Microbiol..

[10]  H. Keyvani,et al.  Comparison of Acyclovir and Multistrain Lactobacillus brevis in Women with Recurrent Genital Herpes Infections: a Double-Blind, Randomized, Controlled Study , 2018, Probiotics and Antimicrobial Proteins.

[11]  H. Keyvani,et al.  Oral immunization with recombinant Lactococcus lactis NZ9000 expressing human papillomavirus type 16 E7 antigen and evaluation of its immune effects in female C57BL/6 mice , 2018, Journal of medical virology.

[12]  H. Keyvani,et al.  Extracellular overproduction of recombinant Iranian HPV-16 E6 oncoprotein in Lactococcus lactis using the NICE system , 2018, Future Virology.

[13]  K. Kawana,et al.  Optimization of human papillomavirus (HPV) type 16 E7-expressing lactobacillus-based vaccine for induction of mucosal E7-specific IFNγ-producing cells. , 2018, Vaccine.

[14]  W. Shi,et al.  Oral immunization with a Lactobacillus casei‐based anti‐porcine epidemic diarrhoea virus (PEDV) vaccine expressing microfold cell‐targeting peptide Co1 fused with the COE antigen of PEDV , 2018, Journal of applied microbiology.

[15]  H. Keyvani,et al.  Codon optimization of Iranian human papillomavirus Type 16E6oncogene forLactococcus lactissubsp.cremorisMG1363 , 2017 .

[16]  H. Keyvani,et al.  Efficient production and optimization of E7 oncoprotein from Iranian human papillomavirus type 16 in Lactococcus lactis using nisin-controlled gene expression (NICE) system. , 2017, Microbial pathogenesis.

[17]  Qinjian Zhao,et al.  Expanded strain coverage for a highly successful public health tool: Prophylactic 9-valent human papillomavirus vaccine , 2017, Human vaccines & immunotherapeutics.

[18]  V. Azevedo,et al.  Use of Wild Type or Recombinant Lactic Acid Bacteria as an Alternative Treatment for Gastrointestinal Inflammatory Diseases: A Focus on Inflammatory Bowel Diseases and Mucositis , 2017, Front. Microbiol..

[19]  H. Keyvani,et al.  Codon Usage Optimization and Construction of Plasmid Encoding Iranian Human Papillomavirus Type 16 E7 Oncogene for Lactococcus Lactis Subsp. Cremoris MG1363 , 2017, Asian Pacific journal of cancer prevention : APJCP.

[20]  R. Franconi,et al.  A plant protein signal sequence improved humoral immune response to HPV prophylactic and therapeutic DNA vaccines , 2017, Human vaccines & immunotherapeutics.

[21]  N. Christensen,et al.  Chimeric L2-Based Virus-Like Particle (VLP) Vaccines Targeting Cutaneous Human Papillomaviruses (HPV) , 2017, PloS one.

[22]  L. Mariani,et al.  Targeting immune response with therapeutic vaccines in premalignant lesions and cervical cancer: hope or reality from clinical studies , 2016, Expert review of vaccines.

[23]  Li Pan,et al.  Lactic acid bacteria as mucosal delivery vehicles: a realistic therapeutic option , 2016, Applied Microbiology and Biotechnology.

[24]  R. Amara,et al.  Oral Immunization with a Recombinant Lactococcus lactis–Expressing HIV-1 Antigen on Group A Streptococcus Pilus Induces Strong Mucosal Immunity in the Gut , 2015, The Journal of Immunology.

[25]  L. Bermúdez-Humarán,et al.  Construction d’un vecteur d’expression chez Lactococcus lactis basée sur la production d’une protéine ancrée de Papillomavirus humain 16 E2/E7 , 2015 .

[26]  R. Rangel-ColmeneroBlanca,et al.  Enhancement of Ad-CRT/E7-mediated antitumor effect by preimmunization with L. lactis expressing HPV-16 E7. , 2014 .

[27]  K. Oda,et al.  Oral vaccination against HPV E7 for treatment of cervical intraepithelial neoplasia grade 3 (CIN3) elicits E7-specific mucosal immunity in the cervix of CIN3 patients. , 2014, Vaccine.

[28]  E. Tartour,et al.  Mucosal vaccines , 2014, Human vaccines & immunotherapeutics.

[29]  E. James,et al.  Switch over from intravenous to oral therapy: A concise overview , 2014, Journal of pharmacology & pharmacotherapeutics.

[30]  Jianhua Yang,et al.  Intranasal immunization with recombinant Lactococci carrying human papillomavirus E7 protein and mouse interleukin-12 DNA induces E7-specific antitumor effects in C57BL/6 mice , 2013, Oncology letters.

[31]  E. Garcia-Fruitós.  Lactic acid bacteria: a promising alternative for recombinant protein production , 2012, Microbial Cell Factories.

[32]  S. Kōzuma,et al.  Adjuvant effect of Japanese herbal medicines on the mucosal type 1 immune responses to human papillomavirus (HPV) E7 in mice immunized orally with Lactobacillus-based therapeutic HPV vaccine in a synergistic manner. , 2012, Vaccine.

[33]  M. Cha,et al.  Antiviral activity of Bifidobacterium adolescentis SPM1005-A on human papillomavirus type 16 , 2012, BMC Medicine.

[34]  Jong-Sup Park,et al.  Oral administration of HPV-16 L2 displayed on Lactobacillus casei induces systematic and mucosal cross-neutralizing effects in Balb/c mice. , 2012, Vaccine.

[35]  M. Olivier,et al.  Immunization against Leishmania major Infection Using LACK- and IL-12-Expressing Lactococcus lactis Induces Delay in Footpad Swelling , 2012, PloS one.

[36]  Mohammed Bahey-El-Din,et al.  Lactococcus lactis-based vaccines from laboratory bench to human use: an overview. , 2012, Vaccine.

[37]  J. Chatel,et al.  Lactococci and lactobacilli as mucosal delivery vectors for therapeutic proteins and DNA vaccines , 2011, Microbial cell factories.

[38]  Jian Chen,et al.  Evaluation of Oral Immunization with Recombinant Avian Influenza Virus HA1 Displayed on the Lactococcus lactis Surface and Combined with the Mucosal Adjuvant Cholera Toxin Subunit B , 2011, Clinical and Vaccine Immunology.

[39]  M. Levine,et al.  Immunology of gut mucosal vaccines , 2011, Immunological reviews.

[40]  R. Elizondo-Omaña,et al.  Efficient secretion of a modified E7 protein from human papilloma virus type‐16 by Lactococcus lactis , 2010, Letters in applied microbiology.

[41]  M. Sung,et al.  Human papillomavirus type 16 E6-specific antitumor immunity is induced by oral administration of HPV16 E6-expressing Lactobacillus casei in C57BL/6 mice , 2010, Cancer Immunology and Immunotherapy.

[42]  S. Kōzuma,et al.  Oral immunization with a Lactobacillus casei vaccine expressing human papillomavirus (HPV) type 16 E7 is an effective strategy to induce mucosal cytotoxic lymphocytes against HPV16 E7. , 2010, Vaccine.

[43]  C. Christodoulou,et al.  Human papilloma viruses and cancer in the post-vaccine era. , 2009, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[44]  K. Ley,et al.  Role of beta7 integrins in intestinal lymphocyte homing and retention. , 2009, Current molecular medicine.

[45]  P. Langella,et al.  Heterologous production of human papillomavirus type-16 L1 protein by a lactic acid bacterium , 2009, BMC Research Notes.

[46]  S. Radulović,et al.  The first clinical use of a live-attenuated Listeria monocytogenes vaccine: a Phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix. , 2009, Vaccine.

[47]  E. Dunne,et al.  A review of prophylactic human papillomavirus vaccines: Recommendations and monitoring in the US , 2008, Cancer.

[48]  R. Dattwyler,et al.  Oral Immunization with Recombinant Lactobacillus plantarum Induces a Protective Immune Response in Mice with Lyme Disease , 2008, Clinical and Vaccine Immunology.

[49]  M. Olivier,et al.  Innate inflammatory responses to the Gram-positive bacterium Lactococcus lactis. , 2008, Vaccine.

[50]  J. Wells,et al.  Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria , 2008, Nature Reviews Microbiology.

[51]  A. Farnoud,et al.  Recent Advances in High Cell Density Cultivation for Production of Recombinant Protein , 2008 .

[52]  Young Bong Kim,et al.  Induction of mucosal and systemic immune responses following oral immunization of mice with Lactococcus lactis expressing human papillomavirus type 16 L1. , 2007, Vaccine.

[53]  S. Wilczynski,et al.  A phase II study of Hsp-7 (SGN-00101) in women with high-grade cervical intraepithelial neoplasia. , 2007, Gynecologic oncology.

[54]  R. Roden,et al.  Protection of Rabbits against Challenge with Rabbit Papillomaviruses by Immunization with the N Terminus of Human Papillomavirus Type 16 Minor Capsid Antigen L2 , 2007, Journal of Virology.

[55]  M. Sung,et al.  Oral administration of human papillomavirus type 16 E7 displayed on Lactobacillus casei induces E7‐specific antitumor effects in C57/BL6 mice , 2006, International journal of cancer.

[56]  D. Lowy,et al.  Chapter 12: Prophylactic HPV vaccines: underlying mechanisms. , 2006, Vaccine.

[57]  Ramasamy,et al.  Immunogenicity of a malaria parasite antigen displayed by Lactococcus lactis in oral , 2006 .

[58]  P. Kozlowski,et al.  Mucosal vaccines: the promise and the challenge , 2006, Nature Reviews Immunology.

[59]  G. Pérez-Martínez,et al.  Production of Human Papillomavirus Type 16 L1 Virus-Like Particles by Recombinant Lactobacillus casei Cells , 2006, Applied and Environmental Microbiology.

[60]  S. Rabot,et al.  A Novel Mucosal Vaccine Based on Live Lactococci Expressing E7 Antigen and IL-12 Induces Systemic and Mucosal Immune Responses and Protects Mice against Human Papillomavirus Type 16-Induced Tumors , 2005, The Journal of Immunology.

[61]  V. Azevedo,et al.  Cell-surface display of E7 antigen from human papillomavirus type-16 in Lactococcus lactis and in Lactobacillus plantarum using a new cell-wall anchor from lactobacilli , 2005, Journal of drug targeting.

[62]  Y. Le Loir,et al.  An inducible surface presentation system improves cellular immunity against human papillomavirus type 16 E7 antigen in mice after nasal administration with recombinant lactococci. , 2004, Journal of medical microbiology.

[63]  Y. Le Loir,et al.  Mice immunization with live lactococci displaying a surface anchored HPV-16 E7 oncoprotein. , 2003, FEMS microbiology letters.

[64]  M. Sirard,et al.  Making recombinant proteins in animals--different systems, different applications. , 2003, Trends in biotechnology.

[65]  Jean Paul Remon,et al.  Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10 , 2003, Nature Biotechnology.

[66]  C. Crum,et al.  Immunotherapy of human cervical high-grade cervical intraepithelial neoplasia with microparticle-delivered human papillomavirus 16 E7 plasmid DNA. , 2003, American journal of obstetrics and gynecology.

[67]  H. Kitchener,et al.  Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[68]  J. Palefsky,et al.  Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a Phase I study of ZYC101. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[69]  Y. Le Loir,et al.  Production of Human Papillomavirus Type 16 E7 Protein in Lactococcus lactis , 2002, Applied and Environmental Microbiology.

[70]  C. Guzmán,et al.  Use of live bacterial vaccine vectors for antigen delivery: potential and limitations. , 2001, Vaccine.

[71]  M. Médici,et al.  Gut mucosal immunostimulation by lactic acid bacteria. , 2000, Biocell : official journal of the Sociedades Latinoamericanas de Microscopia Electronica ... et. al.

[72]  S. Wilczynski,et al.  A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[73]  T. Out,et al.  Epidemiologic and mucosal immunologic aspects of HPV infection and HPV-related cervical neoplasia in the lower female genital tract: A review , 2000, International Journal of Gynecologic Cancer.

[74]  G. Parham,et al.  Induction of Human Papillomavirus-Specific CD4+ and CD8+ Lymphocytes by E7-Pulsed Autologous Dendritic Cells in Patients with Human Papillomavirus Type 16- and 18-Positive Cervical Cancer , 1999, Journal of Virology.

[75]  M. Stanley,et al.  Expression of human papillomavirus type 16 L1 protein in Escherichia coli: denaturation, renaturation, and self-assembly of virus-like particles in vitro. , 1998, Virology.

[76]  J. Hickling,et al.  Construction and characterisation of a recombinant vaccinia virus expressing human papillomavirus proteins for immunotherapy of cervical cancer , 1996, Vaccine.

[77]  M. Schiffman,et al.  The Natural History of Human Papillomavirus Infection in Relation to Cervical Cancer , 2020 .

[78]  H. Keyvani,et al.  Protection against human papillomavirus type 16-induced tumors in C57BL/6 mice by mucosal vaccination with Lactococcus lactis NZ9000 expressing E6 oncoprotein. , 2019, Microbial pathogenesis.

[79]  A. Riazi,et al.  Protection against human papillomavirus type 16-induced tumors in mice using non-genetically modified lactic acid bacteria displaying E7 antigen at its surface , 2013, Applied microbiology and biotechnology.

[80]  C. Hung,et al.  Perspectives for preventive and therapeutic HPV vaccines. , 2010, Journal of the Formosan Medical Association = Taiwan yi zhi.

[81]  C. Rodríguez-Padilla,et al.  Fusion to a Carrier Protein and a Synthetic Propeptide Enhances E7 HPV‐16 Production and Secretion in Lactococcus lactis , 2003, Biotechnology progress.

[82]  John Mao,et al.  Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.